Psilocybin - Silo Pharma
Alternative Names: Psilocybin-Silo PharmaLatest Information Update: 31 Mar 2023
At a glance
- Originator Silo Pharma
- Developer Dominari Holdings; Silo Pharma
- Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
- Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease
- Research Cancer
Most Recent Events
- 27 Jul 2021 AIkido Pharma receives Notice of Allowance from US Patent and Trademark Office (US PTO) for use of proprietary central nervous system (CNS) homing peptides including psilocybin in USA
- 07 Apr 2021 Silo Pharma files for patent protection with the United States Patent and Trademark Office (USPTO) for psilocybin in USA
- 18 Feb 2021 University of Maryland Baltimore in-licenses peptides from Silo Pharma